We have located links that may give you full text access.
Switch to Gliflozins and Biventricular Function Improvement in Patients with Chronic Heart Failure and Diabetes Mellitus.
Clinical Physiology and Functional Imaging 2023 October 6
BACKGROUND: SGLT2 inhibitors have been shown to reduce hospitalization in patients with chronic heart failure (CHF). The cardioprotective mechanisms of gliflozins however have not been fully elucidated. Aim of this study was therefore to evaluate the effect of SGLT2 inhibitors on right and left ventricular function in patients with diabetes and HF.
METHODS: Seventy-eight patients with diabetes and CHF were enrolled in the study and followed up; 38 started treatment with SGLT2i, while the remaining 40 continued their previous antidiabetic therapy. All patients underwent conventional, TDI and strain echocardiography in an ambulatory setting, at the beginning and after 3 months of therapy with SGLT2i.
RESULTS: After 3 months of therapy with SGLT2i, echocardiographic parameters assessing both left and right ventricular dimensions and function were found as significantly improved in patients switching to SGLT2i than control group: LVEF (45±9% vs 40±8%, p<0.001), LVEDD (54±6.5 vs 56±6.5 mm, p<0.01), GLS (-13±4% vs -10±3%, p<0.001), TAPSE (21±3 vs 19±3 mm, p<0.001), RV S' (13±2.5 vs 11±2, p<0.001), and PAsP (24±8 vs 31±9 mmHg, p<0.001). Also mitral (1.0±0.5 vs 1.3±0.5, p<0.01) and tricuspid regurgitation (1.0±0.5 vs 1.3±0.5, p<0.01) improved after SGLT2i therapy. Changes were not statistically significant in patients not treated with SGLT2i (p n.s. in all cases).
CONCLUSIONS: In a real-world scenario, treatment with SGLT2i in patients with CHF and diabetes is associated with an improvement in both left and right ventricular function assessed at echocardiography. These data may explain potential anti-remodelling effects of gliflozins. This article is protected by copyright. All rights reserved.
METHODS: Seventy-eight patients with diabetes and CHF were enrolled in the study and followed up; 38 started treatment with SGLT2i, while the remaining 40 continued their previous antidiabetic therapy. All patients underwent conventional, TDI and strain echocardiography in an ambulatory setting, at the beginning and after 3 months of therapy with SGLT2i.
RESULTS: After 3 months of therapy with SGLT2i, echocardiographic parameters assessing both left and right ventricular dimensions and function were found as significantly improved in patients switching to SGLT2i than control group: LVEF (45±9% vs 40±8%, p<0.001), LVEDD (54±6.5 vs 56±6.5 mm, p<0.01), GLS (-13±4% vs -10±3%, p<0.001), TAPSE (21±3 vs 19±3 mm, p<0.001), RV S' (13±2.5 vs 11±2, p<0.001), and PAsP (24±8 vs 31±9 mmHg, p<0.001). Also mitral (1.0±0.5 vs 1.3±0.5, p<0.01) and tricuspid regurgitation (1.0±0.5 vs 1.3±0.5, p<0.01) improved after SGLT2i therapy. Changes were not statistically significant in patients not treated with SGLT2i (p n.s. in all cases).
CONCLUSIONS: In a real-world scenario, treatment with SGLT2i in patients with CHF and diabetes is associated with an improvement in both left and right ventricular function assessed at echocardiography. These data may explain potential anti-remodelling effects of gliflozins. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app